Piper Jaffray Starts Aimmune Therapeutics (AIMT) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
BofA/Merrill Lynch Starts Aimmune Therapeutics (AIMT) at Buy
August 31, 2015 7:43 AM EDTBofA/Merrill Lynch initiated coverage on Aimmune Therapeutics (NASDAQ: AIMT) with a Buy rating and a price target of $36.00.
For an analyst ratings summary and ratings history on Aimmune Therapeutics click here. For more ratings news on Aimmune Therapeutics click here.
Shares of Aimmune Therapeutics closed at $21.11 yesterday.
... MoreCredit Suisse Starts Aimmune Therapeutics (AIMT) at Outperform
August 31, 2015 7:12 AM EDTCredit Suisse initiates coverage on Aimmune Therapeutics (NASDAQ: AIMT) with a Outperform rating and a price target of $44.00.
Analyst V. Divan commented, "We see AIMT as one of the leaders in developing treatments to help manage life-threatening food allergies, with... More
